MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for Solid Tumors

 MSD Signs a Clinical Trial Collaboration with Ascentage Pharma for Solid Tumors

MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies

Shots:

  • Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda, to evaluate its safety and efficacy in solid tumors (i,e., NSCLC, melanoma, Urothelial cancer, Liposarcoma, MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment)
  • The companies will exchange information about the study with the access of the joint development committee. The P-II trial is being initiated and expected to enroll 80 patients in multiple sites across the US
  •  APG-115 is a small-molecule inhibitor of the MDM2-p53 PPI administered orally and has been commenced in three trials in the US and is also the first MDM2-p53 inhibitor to enter in clinical studies in China. Additionally, the P-Ib trial data is being published in ASCO 2020 showing well-tolerated and with anti-tumor effects in several tumor types

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post